ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

Nasopharyngeal Neoplasms Clinical Trial

— ADVANCE  

Official title:

ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02874651
• Other study ID #: Ahead-N301
• Status: Terminated
• Phase: Phase 2
• Start date: October 2016
• Est. completion date: August 27, 2020

Study information

• Verified date: December 2021
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. The purpose is to evaluate the survival in these patients treated with apatinib (YN968D1), an inhibitor of vascular endothelial growth factor receptor (phase IIa) and to compare the survival in these patients treated with apatinib versus placebo (phase IIb).

Description:

This study has two parts. In the single arm phase IIa part, we will enroll 25 patients that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. All patients will receive apatinib. The purpose is to evaluate the disease free-survival (DFS) in these patients treated with apatinib. In the phase IIb part, patients will be randomized to apatinib or placebo in a ratio of 1:1. The estimated sample size is 78 in phase IIb. However, the final sample size in phase IIb will be determined based on results of the phase IIa part.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: August 27, 2020
• Est. primary completion date: November 29, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Biopsy proven nasopharyngeal carcinoma, with detectable pretreatment plasma EBV DNA

2. Have detectable plasma EBV DNA at the end of (+/- 1 week) curative radiotherapy or chemoradiotherapy (radiation dose > 66Gy), determined by the central lab

3. No clinical evidence of persistent loco-regional disease

4. No evidence of distant metastasis, based upon skeletal scintigraphy, chest X-ray examination, and liver ultrasound or other appropriate workup (e.g., CT, MRI or positron emission tomography (PET)/CT]) within 21 days prior to registration

5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

6. Anticipated survival >= 3 months

7. Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

8. Platelets > 80,000 cells/mm^3

9. Hemoglobin >= 8.0 g/dl (no transfusion within the last 14 days)

10. Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

11. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x institutional ULN

12. Creatinine clearance (CC) >= 50 ml/min estimated by Cockcroft-Gault formula

Exclusion Criteria:

1. Patients with stage III-IV disease (American Joint Committee On Cancer/Union for International Cancer Control 7th) and no contraindication to chemotherapy that didn't receive platinum based concurrent chemotherapy during radiation

2. Patients with tumor possibly invaded main vessels (e.g. encasement of the internal jugular artery/vein) at diagnosis; or tumor that, in the judgment of the investigator, likely to invade main vessels and cause life-threatening hemorrhage events during study

3. History of serious hemorrhage events or grade 3 or higher hemorrhage within 4 weeks prior to registration

4. Hypertension that couldn't be well controlled with single medication; unstable angina; angina diagnosed within the last 3 months; myocardial infarction within the last 6 months; cardiac arrhythmia that need long-term medication; grade 2 or higher cardiac dysfunction (NYHA)

5. Proteinuria

6. Coagulation dysfunction or predisposition to hemorrhage; on treatment of anticoagulation medication or vitamin K antagonist; low dose warfarin (1mg po qd) or aspirin (less than 100mg daily) were permitted as long as the international normalized ratio (INR) = < 1.5

7. Thrombosis within the last 1 year, except cured vein thrombosis related to vein indwelling catheter

8. Unhealed bone fracture or chronic unhealed wound

9. Illness that would interfere with oral medication, including dysphagia, chronic diarrhea, or ileus

10. Pregnant or lactating women

11. Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during and within 6 months after study

12. Current drug abuse or mentally disabled

13. History of congenital or acquired immune deficiency disease or organ transplantation

14. Major medical illness, which in the investigator's opinion would endanger the patients or interfere with the completion of therapy and follow up

Related Conditions & MeSH terms

• Carcinoma
• Nasopharyngeal Carcinoma
• Nasopharyngeal Neoplasms

Intervention

Drug:
• Apatinib
Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
• Placebo
Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.

Locations

Country	Name	City	State
China	Affiliated Foshan Hospital of Sun Yat-sen University	Foshan	Guangdong
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong
China	Affiliated Hospital of Guilin Medical University	Guilin	Guangxi

Sponsors (3)

Lead Sponsor	Collaborator
Sun Yat-sen University	First People's Hospital of Foshan, Guilin Medical University, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival		3 years
Secondary	overall survival		5 years
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0		2 years
Secondary	Changes in quality of life (QOL) as assessed by EORTC QLQ-C30		2 years
Secondary	Distance Metastasis Free Survival		3 years
Secondary	locoregional relapse free survival		3 years
Secondary	Correlation of plasma EBV DNA load with the effect of apatinib on survival		3 years
Secondary	Correlation of pretreatment serum VEGF level with the effect of apatinib on survival		3 years
Secondary	Correlation of pretreatment serum VEGFR-2 level with the effect of apatinib on survival		3 years
Secondary	Correlation of adverse event (hypertension) with the effect of apatinib on survival		3 years
Secondary	Correlation of adverse event (hand-foot syndrome) with the effect of apatinib on survival		3 years
Secondary	Correlation of the change from baseline in serum VEGF level at 4 weeks with the effect of apatinib on survival		3 years
Secondary	Correlation of the change from baseline in serum VEGFR-2 level at 4 weeks with the effect of apatinib on survival		3 years